Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD17002 in Mild to Moderate COVID-19
NCT05541510Phase 3Terminated
- Sponsor
- Advagene Biopharma Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AD-17002 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Advagene Biopharma Co., Ltd. Primary endpoints: Time to disease improvement and Time to achieving the Patient Acceptable Symptom State (PASS). Started Dec 2022; status: terminated.
02
Drugs
AD-17002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05541510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541510.